Literature DB >> 16092921

Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice.

A-O Hovden1, R J Cox, L R Haaheim.   

Abstract

The aim of this study was to compare the kinetics and the magnitude of the humoral immune response to two different influenza vaccine formulations, whole and split virus vaccines. BALB/c mice were immunized intramuscularly with one or two doses (3 weeks apart) of 7.5, 15 or 30 microg of haemagglutinin of monovalent A/Panama/2007/99 (H3N2) split or whole virus vaccine. The two vaccine formulations induced similar kinetics of the antibody-secreting cells response; however, differences in the magnitude were observed in the spleen and bone marrow. Vaccination with whole virus vaccine generally elicited a quicker and higher neutralizing antibody response, particularly after the first dose of vaccine. The two vaccine formulations gave different immunoglobulin G (IgG) subclass profiles. Split virus vaccine stimulated both IgG1 and IgG2a antibodies suggestive of mixed T-helper 1 (Th1) and Th2 response, whereas whole virus vaccine induced mainly an IgG2a antibody response, which is indicative of a dominant Th1 response. The increased immunogenicity of whole virus vaccine in a naïve population could reduce the vaccine concentration needed to provide protective immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092921     DOI: 10.1111/j.1365-3083.2005.01633.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  47 in total

1.  Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice.

Authors:  Deyan Luo; Bing Ni; Peng Li; Wei Shi; Songle Zhang; Yue Han; Liwei Mao; Yangdong He; Yuzhang Wu; Xiliang Wang
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Authors:  Tülin Morçӧl; Brett L Hurst; E Bart Tarbet
Journal:  Vaccine       Date:  2017-07-14       Impact factor: 3.641

3.  Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza.

Authors:  Veronika I Zarnitsyna; Ali H Ellebedy; Carl Davis; Joshy Jacob; Rafi Ahmed; Rustom Antia
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

4.  Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

Authors:  Renée A J van Boxtel; Pauline Verdijk; Otto J de Boer; Elly van Riet; Tjeert T Mensinga; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Inactivated influenza virus vaccines: the future of TIV and QIV.

Authors:  Michael Schotsaert; Adolfo García-Sastre
Journal:  Curr Opin Virol       Date:  2017-05-12       Impact factor: 7.090

Review 6.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

7.  Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.

Authors:  Felix Geeraedts; Vinay Saluja; Wouter ter Veer; Jean-Pierre Amorij; Henderik W Frijlink; Jan Wilschut; Wouter L J Hinrichs; Anke Huckriede
Journal:  AAPS J       Date:  2010-03-02       Impact factor: 4.009

8.  Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies.

Authors:  Solveig Hauge; Abdullah Madhun; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

9.  A pilot study of the immune response to whole inactivated avian influenza H7N1 virus vaccine in mice.

Authors:  Arnt-Ove Hovden; Karl A Brokstad; Diane Major; John Wood; Lars R Haaheim; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2009-01       Impact factor: 4.380

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.